New CEO appointed at Covance Drug Development


New CEO appointed at Covance Drug Development


Laboratory Corporation of America Holdings (LabCorp), a healthcare diagnostics company, has appointed veteran biopharmaceutical executive, John Ratliff, as the chief executive officer (CEO) of Covance Drug Development, its drug development company.

Ratliff will succeed Deborah Keller as CEO, effective October 1 and will be a member of the LabCorp executive committee, where he will report to David King, chairman and CEO of LabCorp.

“John is a highly respected biopharmaceutical leader, with extensive experience in increasingly important roles in the industry,” said King.

“Those who know him and have seen him in action as a leader are impressed by his strength as an executive. He has a stellar reputation in the CRO and pharma sectors. I am delighted that he has agreed to join us at such an exciting time.”

Most recently, Ratliff served as president and CEO of HUYA Bioscience International, a leader in globalizing biopharma innovation. Ratliff’s experience in biopharma also includes nearly ten years at Quintiles, the world’s largest provider of product development and integrated healthcare services, joining as chief financial officer in 2004, becoming chief operating officer in 2006, then president and COO in 2010.

Ratliff said: “LabCorp is a global leader in healthcare innovation, and the addition of Covance has strengthened its position as the world’s leading healthcare diagnostics company.
“The Covance team has an unwavering commitment to quality and service, furthering the company’s strategy of bringing innovative new medicines to patients faster. I am excited to join a highly accomplished leadership team that is deeply committed to improving health and improving lives around the globe.”

LabCorp, US, Healthcare, Risk management, Lab, Appointment, John Ratliff, Deborah Keller